The efficacy and safety of docetaxel for elderly advanced breast cancer patients

Hideya Tashiro, Kojiro Mashino, Kotaro Shibahara, Kazuya Endo, Kyuzo Fujii, Mizuki Ninomiya, Tetsuo Ikeda, Hisanobu Sakata

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


We studied the efficacy and safety of docetaxel (DOC) for elderly breast cancer patients. Between September 1997 and June 2003, five consecutive women with advanced breast cancers who were 75 years of age or older received DOC at a dose of 60 mg/m(2) every three weeks. No premedications to prevent hypersensitive reactions and fluid retention by DOC were given. The number of DOC dosages per case was 5-16 times (12 times the median) and the relative dose intensity (RDI) was 80-100% (95% of medians). Objective partial responses were observed in all patients. The median time to partial response was 21 days (range: 21-50 days). The median time to treatment failure was 12 months (range: 5-22 months). The grade and the frequency of major side effects were the following: leukocytopenia of grade 3 (80%), edema of grade 2-3 (40%), and alopecia of grade 2 (100%). It was concluded from these findings that DOC could be safely and effectively administered to elderly advanced breast cancer patients.

Original languageEnglish
Pages (from-to)453-455
Number of pages3
JournalGan to kagaku ryoho. Cancer & chemotherapy
Issue number3
Publication statusPublished - Jan 1 2007
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'The efficacy and safety of docetaxel for elderly advanced breast cancer patients'. Together they form a unique fingerprint.

Cite this